Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double-digit volume growth” and record new prescriptions (NRX) across multiple quarters. He noted a headwind in 2025 related to gross-to-net and net price per script tied to contracts taken on during the year, but said the company expects a “clean year” in 2026 from a contracting and access perspective.On the commercial side, Gano said the company generated “just north o ...

Summary of Neurocrine Biosciences Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date of Conference**: March 17, 2026 - **Key Speakers**: Kyle Gano (CEO), Todd Tushla (Head of IR) Key Points 1. Financial Performance - **2025 Revenue**: Approximately $2.8 billion, representing a **22% year-over-year growth** [4] - **Ingrezza Revenue**: $2.51 billion in 2025, with a **9% year-over-year growth** and double-digit volume growth [5] - **2026 Revenue Guidance**: Expected to be between **$2.7 billion and $2.8 billion** [11] - **Price Trends**: Anticipated **4%-5% price decline** year-over-year for Ingrezza due to expanded access [12] 2. Product Performance - **Ingrezza**: - Eighth year of commercialization with strong sales performance. - Focus on expanding prescriber base, targeting **30% new prescribers** [6] - Anticipated strong year with **double-digit volume growth** [31] - **CRENESSITY**: - First year of commercial sales generated **$300 million** in revenue, capturing **10% of the CH market** [7] - High reimbursement rates with **80% of dispensed scripts reimbursed** [7] - Focus on educational support for physicians and patients to change the standard of care [8] 3. Pipeline and Future Developments - **Phase 3 Trials**: - Osavampator and direclidine expected to deliver data in **2027** [8] - NBI-570 (M1M4 dual agonist) in schizophrenia and NBI-890 (next-generation VMAT2 inhibitor) in phase 2 trials [9][10] - **Next-Generation VMAT2 Program**: - Focus on long-acting injectable formulations to improve patient compliance [72] - **CRF1 Antagonist (NBIP-1435)**: - In phase 1, moving to phase 2/3 later this year, offering a long-acting injectable option [80] 4. Market Dynamics and Competitive Landscape - **Market Access**: - 70% of TD and HD patients under existing contracts, providing a strong market position [36] - **Competitor Analysis**: - Teva's MFP implementation in 2027 and 2028 may impact pricing strategies [36] - **Regulatory Environment**: - Ongoing negotiations with Medicare plans for 2027, with expectations for adjacent MFP products [37] 5. Strategic Focus - **Execution and Data Delivery**: - Emphasis on executing current strategies and delivering data across phase 2 and phase 3 programs in 2027 [10] - **Sustainable Innovation**: - Commitment to a diversified pipeline and innovation engine to support long-term growth [86] 6. Additional Insights - **Patient Compliance**: - Importance of addressing patient reauthorization processes and maintaining access to prescriptions [44] - **Market Sensitivity**: - Anticipation of emotional responses to new patient start forms, with a focus on consistent growth trends [42] Conclusion Neurocrine Biosciences is positioned for continued growth with a strong financial profile, a diversified product portfolio, and a robust pipeline of upcoming clinical data. The company is focused on execution and market access strategies to navigate competitive pressures and regulatory challenges while aiming to enhance patient care through innovative therapies.

Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 years as an executive at Eli Lilly and Company. He had broad responsibility across Lilly's drug and device development and the delivery of innovative solutions spanning preclinical development through global manufacturing. Dr. Ratz contributed to the successful development and registration of more than 25 medicines across multiple therapeutic areas and drug modaliti ...

Neurocrine Biosciences Conference Call Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date**: March 09, 2026 - **Key Products**: INGREZZA and CRENESSITY Core Industry Insights - **Market Position**: Neurocrine has two approved products, INGREZZA and CRENESSITY, with a revenue guidance of $2.7 billion to $2.8 billion for INGREZZA in 2026, reflecting significant growth potential [8][11] - **Sales Force Expansion**: A recent expansion of the sales force is expected to enhance patient outreach and support for tardive dyskinesia treatment [8][10] Product Performance - **INGREZZA**: - Launched 9 years ago, still experiencing double-digit growth [8] - Expected to achieve nearly 10% growth in 2026, with volume growth projected at 14%-15% after accounting for price declines [61] - Currently, only 10% of the 800,000 patients with tardive dyskinesia are on VMAT2 inhibitors, indicating substantial market potential [61] - **CRENESSITY**: - First new treatment for congenital adrenal hyperplasia (CAH) in over 70 years, generating over $300 million in sales in its first year [9] - Targeting a patient population of approximately 20,000 with classic CAH, with an additional 60,000 to 80,000 with non-classic CAH [17] - The launch is considered one of the top 10% of rare disease launches historically [9] Financial Health - **Cash Position**: Neurocrine holds over $2.5 billion in cash with no debt, indicating strong financial stability [11] - **R&D Investment**: The company allocates around 35% of its revenue back into research and development, supporting a robust pipeline [10][86] Growth Strategies - **Patient Acquisition**: - Less than 50% of the initial 2,000 patients for CRENESSITY came from Centers of Excellence, indicating room for growth in this area [20] - The company is optimistic about increasing patient access through ongoing efforts and clinician engagement [20][28] - **Reimbursement Success**: - Over 80% of prescriptions for CRENESSITY are being reimbursed, with a strong foundation laid for reimbursement processes prior to launch [30][28] - The reimbursement landscape is favorable, with a manageable process for obtaining authorizations [28] Future Prospects - **Clinical Trials**: Two late-stage Phase 3 trials are underway, focusing on schizophrenia and depression, with results expected in 2027 and 2028 [10] - **Obesity Market Entry**: Neurocrine is exploring opportunities in the obesity space, leveraging its existing expertise and planning to initiate trials soon [86][82] Key Challenges - **Market Competition**: The company acknowledges the competitive landscape in obesity and is focused on differentiating its offerings [85] - **Investment Scrutiny**: There are concerns regarding high spending levels, but the company emphasizes long-term growth over short-term profitability [87][89] Conclusion Neurocrine Biosciences is positioned for significant growth with its innovative products and strong financial foundation. The company is actively expanding its market presence while investing in research and development to sustain its pipeline and address unmet medical needs.

Neurocrine Biosciences Conference Call Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date**: March 09, 2026 - **Key Products**: INGREZZA and CRENESSITY Core Industry Insights - **Market Position**: Neurocrine has two approved products, INGREZZA and CRENESSITY, with a revenue guidance of $2.7 billion to $2.8 billion for INGREZZA in 2026, indicating significant growth potential in the biopharma sector [5][8] - **Sales Force Expansion**: A recent expansion of the sales force is expected to enhance patient outreach and support for tardive dyskinesia treatment [5][8] Product Performance INGREZZA - **Market Presence**: INGREZZA has been on the market for 9 years, showing double-digit growth [5] - **Revenue Growth**: Expected to achieve approximately 10% growth, with volume growth projected at 14%-15% after accounting for a 4%-5% decrease in net price [60][63] - **Patient Access**: Only 10% of the estimated 800,000 patients with tardive dyskinesia are currently receiving VMAT2 inhibitors, indicating a substantial market opportunity [63] CRENESSITY - **Launch Success**: CRENESSITY generated over $300 million in sales in its first year, helping 2,000 patients with congenital adrenal hyperplasia (CAH) [6][10] - **Patient Population**: There are approximately 20,000 patients with classic CAH and an additional 60,000-80,000 with non-classic CAH [15] - **Growth Potential**: The company believes that 80% of classic CAH patients could benefit from CRENESSITY, suggesting a significant market opportunity [23] Financial Health - **Cash Reserves**: Neurocrine has over $2.5 billion in cash and no debt, allowing for continued investment in R&D [8][9] - **R&D Investment**: The company allocates around 35% of its revenue back into R&D, supporting its long-term growth strategy [7][88] Reimbursement and Market Access - **Reimbursement Success**: Over 80% of prescriptions for CRENESSITY are being reimbursed, with a strong foundation laid for patient access through prior engagement with payers [31][29] - **Patient Enrollment**: The company has seen fluctuations in patient enrollment, which is typical for rare disease launches, but remains optimistic about future growth [21][22] Strategic Focus - **Obesity Market Entry**: Neurocrine is exploring opportunities in the obesity market, leveraging its existing expertise in endocrinology [82][87] - **Business Development**: The company has engaged in several smaller business development transactions to enhance its pipeline, focusing on early-stage assets [92][96] Key Takeaways - **Long-term Vision**: Neurocrine aims to build a market cap of $30 billion to $50 billion by sustaining a robust R&D pipeline and commercializing effective products [8] - **Patient-Centric Approach**: The company emphasizes the importance of patient outcomes and safety, particularly in pediatric populations, to drive adoption of its therapies [19][20] This summary encapsulates the key points discussed during the Neurocrine Biosciences conference call, highlighting the company's strategic direction, product performance, and market opportunities.

Neurocrine Biosciences FY Conference Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Key Products**: INGREZZA and CRENESSITY - **Market Position**: Operating from a position of strength with two commercial value drivers and a strong R&D engine [4][8] Core Strengths - **Commercial Value Drivers**: - **INGREZZA**: Experienced double-digit volume growth in 2025, with expectations for continued growth in 2026. It is the lowest-priced VMAT2 inhibitor with the best clinical performance [5][6] - **CRENESSITY**: Achieved over $300 million in sales in its first year post-approval for congenital adrenal hyperplasia, indicating a strong trajectory towards blockbuster status [6][12] - **R&D Engine**: A fully operational and sustainable R&D engine capable of producing multiple high-quality programs, particularly in neurology and psychiatry [7][8] - **Financial Strength**: High-margin, cash-generative business model providing resiliency and optionality for capital allocation [8][9] - **Proven Team**: Experienced in launching medicines and executing clinical studies [9][10] Challenges and Risks - **IRA Impact**: The Inflation Reduction Act (IRA) poses a headwind for the industry and specifically for INGREZZA, with preparations in place for its implementation in 2029 [10][11] - **CRENESSITY Launch Dynamics**: Initial patient start fluctuations are common in orphan drug launches, but underlying demand remains strong [11][12] - **Investment Strategy**: Focus on long-term growth rather than maximizing short-term profits, with investments in SG&A and R&D aligned with peer benchmarks [12][13] Key Priorities for 2026 - Achieve double-digit volume growth for INGREZZA [14] - Successfully scale the CRENESSITY launch and expand the patient population [14] - Execute on the mid to late-stage pipeline to deliver data in the coming years [14] Market Dynamics - **INGREZZA Growth Drivers**: Continued growth in the VMAT2 category, increasing prevalence of tardive dyskinesia (TD), and expanding prescriber base [18][19] - **CRENESSITY Market Penetration**: Currently treating about 10% of the total prevalent patient pool, with expectations for continued growth [25][26] R&D Strategy - **Therapeutic Areas**: Diversification into neurology, endocrinology, and neuroimmunology while maintaining a strong focus on neuropsychiatry [40][41] - **Modalities**: Transitioning from a small molecule focus to include peptides, proteins, antibodies, and gene therapy [42] - **Innovation Philosophy**: Emphasis on pragmatic innovation targeting proven biology, with a balanced portfolio of high-confidence targets [43] Obesity Market Strategy - **Emerging Focus**: Neurocrine is positioning itself in the obesity market, emphasizing quality weight loss and addressing comorbidities [45][46] - **Pipeline Development**: Plans to advance multiple molecules targeting obesity, leveraging existing expertise in CNS [49][50] Financial Projections - **Revenue Estimates**: Projected revenue of $301 million for CRENESSITY in 2026, with potential for significant growth by 2030 [29][32] Conclusion - Neurocrine Biosciences is well-positioned for growth with a strong product portfolio, robust R&D capabilities, and a clear strategy for navigating market challenges and opportunities in the coming years [14][44]

Core Insights - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is identified as one of the most oversold pharmaceutical stocks, with a recent price target reduction by Truist from $169 to $140 while maintaining a Buy rating [2][8] Financial Performance - The company reported strong financial results for Q4 and the full year 2025, with net product sales increasing by 29% year-over-year to $798.3 million in Q4 and 22% to $2.83 billion for the entire year [3] - Sales from INGREZZA reached $657.5 million in Q4 and $2.51 billion for the full year, reflecting annual growth of 7% and 9%, respectively, driven by strong prescription demand but impacted by lower net pricing due to formulary access investments [4] - CRENESSITY contributed $135.3 million in Q4 sales and $301.2 million for the year, supported by robust patient enrollment and reimbursement coverage [4] Company Overview - Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related disorders, emphasizing innovative therapies for conditions such as movement disorders, epilepsy, and hormonal diseases [5]

Industry Overview - The pharmaceutical sector in the United States was valued at $634.32 billion in 2024 and is projected to grow to $883.97 billion by 2030, driven primarily by customized medication, which is expected to increase from $169.56 billion in 2024 to $307.04 billion by 2033 at a CAGR of 6.82% [2] - The industry has undergone significant changes due to policy shifts during Donald Trump's administration, including a "Build It Here" campaign to boost domestic manufacturing and a 100% tariff on imported brand-name medications [3] - Regulatory reforms have expedited the approval of generic and biosimilar products, contributing to a larger movement toward cost containment and pharmaceutical self-sufficiency [3] Market Challenges - The pharmaceutical industry faces risks such as the impending $350 billion global patent cliff due to the loss of market exclusivity for key medications like Keytruda and Eliquis [4] - Despite these challenges, growth is expected to be sustained by advancements in gene treatments, biologics, and artificial intelligence [4] - Analysts from Deloitte, PwC, and S&P Global Ratings predict robust credit conditions supported by substantial cash reserves and ongoing industrial innovation [4] Company Highlights - Hims & Hers Health, Inc. (NYSE:HIMS) is identified as one of the most oversold stocks, with a Relative Strength Index (RSI) of 16.68 and a price target upside of 94.39% [9] - The company announced a deal to acquire Eucalyptus for up to $1.15 billion, with plans to finance the agreement through current cash and future U.S. operating cash flows [10][11] - Hims & Hers faced backlash after attempting to launch a $49 oral semaglutide weight-loss pill, leading to a quick reversal of the offering due to regulatory concerns [12] - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is another oversold stock with an RSI of 40.53 and a price target upside of 36.79% [14] - The company reported strong financial results, with Q4 net product sales increasing by 29% year-over-year to $798.3 million and full-year sales reaching $2.83 billion [15] - INGREZZA, one of Neurocrine's products, generated $657.5 million in Q4 sales, reflecting 7% annual growth, supported by strong prescription demand [16]

Core Insights - Neurocrine Biosciences reported $805.5 million in revenue for Q4 2025, marking a year-over-year increase of 28.3% and exceeding the Zacks Consensus Estimate by 2.89% [1] - The company's EPS for the same quarter was $1.88, which is a significant increase from $1.00 a year ago, although it fell short of the consensus estimate of $2.25 by 16.55% [1] Revenue Breakdown - Product sales from INGREZZA reached $657.5 million, slightly below the average estimate of $661.61 million, but still reflecting a year-over-year growth of 6.9% [4] - Total product sales amounted to $798.3 million, surpassing the estimated $788.24 million, with a year-over-year increase of 28.5% [4] - CRENESSITY generated $135.4 million in product sales, exceeding the average estimate of $120.56 million [4] - Collaboration revenue was reported at $7.2 million, above the average estimate of $6.46 million, representing a year-over-year increase of 10.8% [4] - Other product sales were $5.4 million, which is higher than the average estimate of $4.1 million, but this reflects a year-over-year decline of 11.5% [4] Stock Performance - Neurocrine's shares have returned +4.1% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - Neurocrine's total product sales grew to over $2.8 billion, representing a 22% year-over-year growth, driven by INGREZZA and the successful launch of CRENESSITY [11][12] - INGREZZA generated just over $2.5 billion in revenue, up 9% year-over-year, with expectations of sales in the range of $2.7 billion to $2.8 billion in 2026, indicating approximately 10% growth [11][12] - The company's cash position increased by approximately $700 million, from $1.8 billion at the end of 2024 to $2.5 billion at the end of 2025, reflecting strong operating performance [14] Business Line Data and Key Metrics Changes - INGREZZA's performance continues to impress, with record levels of new and total prescriptions, supported by strategic investments in access and sales force expansion [5][11] - CRENESSITY achieved over $300 million in net product sales in its first full year, with prescriptions covering over 10% of the classic congenital adrenal hyperplasia patient population [12][13] - The company expects double-digit volume-driven growth for INGREZZA, supported by continued demand from patients not currently taking a VMAT2 inhibitor [6][11] Market Data and Key Metrics Changes - Approximately 10% of the classic CAH population in the U.S. has been prescribed CRENESSITY, with the potential for further growth as the company expands its reach beyond endocrinologists [22][82] - The market for VMAT2 inhibitors, including INGREZZA, remains underpenetrated, with only about 10% of the prevalent TD population currently taking a VMAT2 inhibitor [23] Company Strategy and Development Direction - Neurocrine aims to lead the VMAT2 category by leveraging its experience with INGREZZA to advance next-generation VMAT2 inhibitors [8] - The company is focused on expanding its pipeline, with late-stage programs in neuropsychiatry and ongoing investments in R&D to support future growth [9][27] - The strategy includes expanding the CRENESSITY sales force and leveraging technology to identify and engage potential prescribers [21][83] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong foundation and momentum entering 2026, with expectations for continued growth and successful execution of its strategies [10][16] - The management team highlighted the importance of ongoing education for prescribers and patients regarding the benefits of CRENESSITY and the limitations of existing treatments [88] Other Important Information - The company achieved its phase I through phase III objectives for the first time in 2025, marking it as the most productive clinical year in its history [9] - Neurocrine's R&D expenses are expected to increase in 2026 due to investments in phase III programs, with a focus on delivering one new medicine every two years at steady state [15][47] Q&A Session Summary Question: Insights on CRENESSITY's early performance and patient dynamics - Management noted that while they are not providing specific guidance for CRENESSITY, they anticipate steady new patient additions and a strong growth year based on positive feedback and demand dynamics [34][51] Question: Impact of receptor occupancy data on future VMAT2 inhibitors - The management highlighted that INGREZZA demonstrated nearly double the VMAT2 target occupancy compared to Austedo XR, indicating superior efficacy, which will inform the development of next-generation VMAT2 inhibitors [38] Question: Barriers to further adoption of CRENESSITY - Management identified lack of knowledge among endocrinologists as a barrier and emphasized the importance of educational efforts to inform prescribers about the benefits of CRENESSITY over traditional glucocorticoid treatments [86]